MedPath

苏州东瑞制药有限公司

Ownership
-
Established
1995-12-08
Employees
-
Market Cap
-
Website
www.dawnrays.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

155

NMPA:155

Drug Approvals

Rivaroxaban Tablets

Product Name
利伐沙班片
Approval Number
国药准字H20258041
Approval Date
Mar 25, 2025
NMPA

Rivaroxaban Tablets

Product Name
利伐沙班片
Approval Number
国药准字H20258040
Approval Date
Mar 25, 2025
NMPA

Atorvastatin Calcium Tablets

Product Name
阿托伐他汀钙片
Approval Number
国药准字H20247276
Approval Date
Nov 7, 2024
NMPA

Atorvastatin Calcium Tablets

Product Name
阿托伐他汀钙片
Approval Number
国药准字H20247275
Approval Date
Nov 7, 2024
NMPA

Rivaroxaban Tablets

Product Name
利伐沙班片
Approval Number
国药准字H20233402
Approval Date
Oct 25, 2024
NMPA

Rosuvastatin Calcium Tablets

Product Name
瑞舒伐他汀钙片
Approval Number
国药准字H20247200
Approval Date
Sep 2, 2024
NMPA

Cefixime Tablets

Product Name
头孢克肟片
Approval Number
国药准字H20247044
Approval Date
May 8, 2024
NMPA

Rosuvastatin Calcium Tablets

Product Name
瑞舒伐他汀钙片
Approval Number
国药准字H20234598
Approval Date
Dec 5, 2023
NMPA

Atorvastatin Calcium Tablets

Product Name
阿托伐他汀钙片
Approval Number
国药准字H20233785
Approval Date
Jun 27, 2023
NMPA

Tenofovir Alafenamide Fumarate Tablets

Product Name
富马酸丙酚替诺福韦片
Approval Number
国药准字H20233688
Approval Date
Jun 7, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 16
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.